hepatitis C

Enanta, among Boston's few profitable biotechs, earns another $30M
Bizjournals.com
Mon, 09/28/15 - 08:41 am
Enanta
AbbVie
hepatitis C
Viekirax
Here are the 5 drug classes with the biggest price gains
Fortune
Wed, 09/23/15 - 10:02 pm
hepatitis C
compounded drugs
diabetes
hemophilia
painkillers
After Harvoni: A pangenotype hep C combo could be Gilead's next breakthrough
BioPharma Dive
Tue, 09/22/15 - 11:45 am
Gilead Sciences
Harvoni
hepatitis C
Sovaldi
Gilead combo drug fights all forms of hep C infection: data
Yahoo/Reuters
Mon, 09/21/15 - 10:51 am
Gilead
hepatitis C
velpatasvir
Sovaldi
Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo
Bidness, ETC
Fri, 09/18/15 - 10:56 am
JNJ
Achillion
hepatitis C
Sovaldi
Gilead Sciences
ACH-3102
odalasvir
Will Gilead Sciences (GILD) Stock Fall on Fewer Hep-C Prescriptions?
TheStreet.com
Fri, 09/11/15 - 05:54 pm
Gilead
hepatitis C
Harvoni
Sovaldi
White House urged to stop states' 'rationing' of hep C drugs
Fierce Pharma
Wed, 08/26/15 - 11:56 am
hepatitis C
Medicaid
Harvoni
Gilead Sciences
AbbVie
Viekira Pak
Why Gilead's hep C scripts are slowing down in Q3
BioPharma Dive
Wed, 08/26/15 - 10:44 am
Gilead
hepatitis C
Harvoni
Sovaldi
Analysts: Gilead's hep C scripts keep slowing, and Q3 sales forecasts should too
Fierce Pharma
Mon, 08/24/15 - 12:00 pm
Gilead
Sovaldi
Harvoni
hepatitis C
Gilead Sciences: Hep-C Prescriptions Still Slowing
Barron's
Fri, 08/21/15 - 05:20 pm
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
After Curing Hepatitis C, Gilead Works to Vanquish More Viruses
Bloomberg
Mon, 08/17/15 - 07:15 pm
Gilead Sciences
hepatitis C
hepatitis B
GS-9620
viruses
Payers Set To Play Hardball On PCSK9 Pricing
Investors.com
Fri, 08/14/15 - 11:22 am
payer negotiation
drug pricing
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
hepatitis C
Express Scripts
Once Disparaged, 'Me-Too' Drugs Crucial For Lower Costs Of Cholesterol, Hepatitis C And Cancer Drugs
Forbes
Tue, 08/11/15 - 09:56 am
me-too drugs
drug pricing
hepatitis C
cancer
Merck Targets Toughest Cases to Gain Hepatitis C Foothold
Bloomberg
Mon, 08/3/15 - 05:10 pm
Merck
Gilead Sciences
AbbVie
hepatitis C
Viekira Pak
Harvoni
Sovaldi
grazoprevir/elbasvir
Gilead Won’t Run Out of Hep C Patients, or Dollars, Anytime Soon
Bloomberg
Thu, 07/30/15 - 10:36 am
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Gilead hepatitis C drugs build road to Japan
Bizjournals.com
Wed, 07/29/15 - 09:56 pm
Gilead
Japan
hepatitis C
Harvoni
Sovaldi
Eyeing big returns, drugmakers ready new hepatitis-C drug launches
Medical Marketing and Media
Wed, 07/29/15 - 09:46 pm
hepatitis C
Merck
grazoprevir/elbasvir
Gilead Sciences
Harvoni
Sovaldi
New drug approval is a win for the Bay State's horse in the hepatitis C race
Bizjournals.com
Tue, 07/28/15 - 12:34 pm
Enanta Pharmaceuticals
AbbVie
Technivie
hepatitis C
Gilead Sciences: Sure, It’s Hep-C But It’s Not Just Hep-C
Barron's
Tue, 07/28/15 - 12:38 am
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Bristol-Myers snags a hep C approval to piggyback on Gilead's blockbuster
Fierce Biotech
Mon, 07/27/15 - 01:28 pm
Bristol-Myers Squibb
Gilead Sciences
hepatitis C
Daklinza
Sovaldi

Pages